ArticleFrontiers in molecular biosciences2025
Habitat imaging with intratumoral radiomics for prediction of axillary response after neoadjuvant chemotherapy in breast cancer patients.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multimodal habitat radiomics based on automated breast volume scanning and conventional ultrasound for risk stratification of biopsy-confirmed BI-RADS 4A breast lesions.Frontiers in oncology · 2026Article
- MRI-based habitat radiomics for preoperative prediction of axillary pathological complete response in breast cancer after neoadjuvant therapy: a multicenter study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale and objectives: Breast cancer remains a leading cause of cancer-related morbidity and mortality globally. This study aimed to develop and validate predictive models for ALN pCR following NAC in breast cancer patients. Materials and methods: We conducted a retrospective analysis involving 189 patients who were diagnosed with primary breast cancer at the Affiliated Hospital of Qingdao University. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was utilized to assess the characteristics of the tumors. Tumor segmentation was performed using itk-SNAP software, followed by voxel clustering to identify distinct habitat-derived regions. Logistic regression (LR) and multilayer perceptron (MLP) models were constructed using these features. Results: The classification model incorporating with habitat-based radiomic features demonstrating superior predictive performance (AUC of 0.88 in training and 0.81 in test for LR). A clinicopathologic signature that includes factors such as age, hormone receptor status, the Ki-67 index, and clinical stage was established, achieving in an AUC of 0.81. To construct a nomogram, we integrated habitat-derived radiomic signature with clinicopathologic signature. This nomogram attained an AUC of 0.92 for the training cohort and 0.89 for the test cohort. Furthermore, calibration and decision curve analyses confirmed the nomogram's reliability and practical applicability in clinical settings. Conclusion: In summary, our results indicate that radiomic features extracted from pre-NAC DCE-MRI can improve the predictive accuracy for ALN pCR following NAC in individuals diagnosed with breast cancer. This finding highlights the promise of personalized treatment strategies for individual patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.